In the US, GLP-1 spending rose from $13 to $72 billion in just five years, making approval tough for patients without diabeteseven as data for arthritis risk and cardiovascular benefits grow
Longer half-life means more drug overlap when you inject early
Our licensed providers evaluate each patient individually before prescribing
Madisen L, Garner Aleena R, Shimaoka D et al (2015) Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance
Every other day dosing is not a standard recommended protocol
Diabetes Healthcare Professionals Consider Whole Person As diabetes healthcare professionals, we want to carefully consider which medication best matches the people in our care, considering individual values and preferences along with co-conditions including diabetes, cardiorenal metabolic co-conditions, MASH, sleep apnea and weight goals